Literature DB >> 17554689

Chikungunya fever in travelers: clinical presentation and course.

Winfried Taubitz1, Jakob P Cramer, Anette Kapaun, Martin Pfeffer, Christian Drosten, Gerhard Dobler, Gerd D Burchard, Thomas Löscher.   

Abstract

BACKGROUND: An outbreak of chikungunya virus infection emerged in the southwest Indian Ocean islands in 2005, spread out to India, and resulted in an ongoing outbreak that has involved >1.5 million patients, including travelers who have visited these areas.
METHODS: Our study investigated 69 travelers who developed signs and symptoms compatible with chikungunya fever after returning home from countries involved in the epidemic. Twenty cases of infection that were confirmed by serological analysis, polymerase chain reaction, and/or cell culture were investigated.
RESULTS: All patients experienced flulike symptoms with fever and joint pain. No serious complications were observed, but 69% of the patients had persistent arthralgia for >2 months, and 13% had it for >6 months. Viral RNA could be detected in blood samples using reverse-transcriptase polymerase chain reaction in 4 of 4 patients who presented to a health care facility during their first week of illness, and the virus was successfully isolated from blood samples obtained from 2 of these patients. Chikungunya virus-specific immunoglobulin M and/or immunoglobulin G antibodies were detected in all patients. However, initial testing of serum samples yielded negative results for 3 of 5 patients during the first week.
CONCLUSIONS: Chikungunya fever must be considered in travelers who develop fever and arthritis after traveling to areas affected by an ongoing epidemic. Related arthritis mainly affects smaller joints and often persists for extended periods. Serological testing may have negative results during the first week of the disease; diagnosis using polymerase chain reaction appears to be more reliable during this time. Travelers to areas of epidemicity should be informed of the risk of infection and of adequate preventive measures, such as protection against mosquitos.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554689     DOI: 10.1086/518701

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  58 in total

1.  Green synthesis of silver nanoparticles from Cassia roxburghii-a most potent power for mosquito control.

Authors:  Udaiyan Muthukumaran; Marimuthu Govindarajan; Mohan Rajeswary
Journal:  Parasitol Res       Date:  2015-08-16       Impact factor: 2.289

2.  Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness.

Authors:  Daniel Ciampi de Andrade; Sylvain Jean; Pierre Clavelou; Radhouane Dallel; Didier Bouhassira
Journal:  BMC Infect Dis       Date:  2010-02-19       Impact factor: 3.090

3.  A nonhuman primate model of chikungunya disease.

Authors:  Stephen Higgs; Sarah A Ziegler
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

4.  Performance of the RealStar Chikungunya virus real-time reverse transcription-PCR kit.

Authors:  Marcus Panning; Markus Hess; Waldemar Fischer; Klaus Grywna; Martin Pfeffer; Christian Drosten
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

Review 5.  Emerging viral diseases.

Authors:  Andrew Pekosz; Gregory E Glass
Journal:  Md Med       Date:  2008

Review 6.  Novel infectious agents causing uveitis.

Authors:  Moncef Khairallah; Soon Phaik Chee; Sivakumar R Rathinam; Sonia Attia; Venu Nadella
Journal:  Int Ophthalmol       Date:  2009-08-27       Impact factor: 2.031

7.  Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.

Authors:  Ryan M Kramer; Yuhong Zeng; Neha Sahni; Lisa A Kueltzo; Richard M Schwartz; Indresh K Srivastava; Lindsey Crane; Sangeeta B Joshi; David B Volkin; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2013-10-15       Impact factor: 3.534

8.  Larvicidal, ovicidal, and oviposition-deterrent activities of four plant extracts against three mosquito species.

Authors:  K P Prathibha; B S Raghavendra; V A Vijayan
Journal:  Environ Sci Pollut Res Int       Date:  2014-02-25       Impact factor: 4.223

9.  Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study.

Authors:  Man-Koumba Soumahoro; Patrick Gérardin; Pierre-Yves Boëlle; Joelle Perrau; Adrian Fianu; Jacques Pouchot; Denis Malvy; Antoine Flahault; François Favier; Thomas Hanslik
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

10.  Prospective study of Chikungunya virus acute infection in the Island of La Réunion during the 2005-2006 outbreak.

Authors:  Frederik Staikowsky; François Talarmin; Philippe Grivard; Abdel Souab; Isabelle Schuffenecker; Karin Le Roux; Marc Lecuit; Alain Michault
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.